Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05954871 · ClinicalTrials.gov registry record · Phase 1

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

A Phase 1 study, sponsored by Genentech.

Completed
Registry status
Phase 1
Development phase
10
Enrollment target

NCT05954871: Completed Phase 1 study, sponsored by Genentech.

NCT05954871 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05954871, a Phase 1 study, has completed, sponsored by Genentech.

COMPLETED
Registry status
Phase 1
Development phase
10 participants
Enrollment target

Study Summary

The main purpose of the study is to evaluate the safety of GDC-1971 in combination with either osimertinib or cetuximab. The study consists of a dose-finding stage followed by an expansion stage.

Interventions

  • DRUG Osimertinib
  • DRUG Cetuximab
  • DRUG GDC-1971

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2024-01-08
Est. Completion 2025-09-16
Phase Phase 1
Genentech

332 total trials

What the finished NCT05954871 record still lists

NCT05954871 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).

The record links to 0 conditions, and to 3 interventions - of which Osimertinib is the first listed.

NCT05954871 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05954871 about?

NCT05954871 is a clinical study titled "Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer". The main purpose of the study is to evaluate the safety of GDC-1971 in combination with either osimertinib or cetuximab. The study consists of a dose-finding stage followed by an expansion stage.

What is the current status of trial NCT05954871?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-01-08. Estimated completion is 2025-09-16.

What interventions are being tested in trial NCT05954871?

The interventions under investigation include: Osimertinib (DRUG), Cetuximab (DRUG), GDC-1971 (DRUG).

Who is sponsoring clinical trial NCT05954871?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05954871's enrollment target sits among peer trials

10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05954871, the US trial registry maintained by the National Library of Medicine. NCT05954871 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.